In what has been a transformative year for ulcerative colitis (UC) treatment, the IL-23 class has solidified its role as a key therapeutic treatment option. With Johnson & Johnson’s Tremfya now ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback